Incyte Corporation

INCY | NASDAQ

Price Alert Chart Builder DCF Calculator

$126.43

+$1.12 (+0.89%)

Sep 21, 2026, 11:04 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.89%

(1D)

Rating

Updated: Sep 9, 2026

84.6

Fundamentals Excellent

Market Sentiment Bullish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $25.63B

1D Range

125.02 127.43

52W Range

81.09 132.60

Valuation (TTM)

PE 15.96

PB 4.00

EV/EBITDA 10.24

Valuation (NTM)

Forward PE 13.67

Forward PEG 0.12

Price Target $130.07

Cash Flow

FCF Yield 7.6%

SBC Adj. FCF Yield 6.8%

SBC Impact -9.8%

Margins

Gross Margin 92.6%

Operating Margin 31.6%

FCF Margin 33.0%

Growth (CAGR)

Revenue 3Y | 5Y 18.3% | 16.4%

Dil EPS 3Y | 5Y 68.9% | 38.9%

FCF 3Y | 5Y 40.1% | 33.7%

Returns

ROA 20.5%

ROE 29.7%

ROIC 24.6%

Financial Health

Net Cash

$4.53B

Current Ratio 4.66

Interest Coverage 790.59

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for ...

Sector Healthcare

Industry Biotechnology

Employees 2,844

IPO Date Nov 3, 1993

Website www.incyte.com

Fiscal Year January - December

Full Company Profile

Latest News

23 hours ago · prnewswire.com

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte

1 day ago · marketbeat.com

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.

4 days ago · seekingalpha.com

Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

5 days ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

6 days ago · zacks.com

INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.

11 days ago · seekingalpha.com

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

12 days ago · seekingalpha.com

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

19 days ago · seekingalpha.com

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.